Medical oncology: Zoledronic acid for breast cancer therapy-induced bone loss

Nature Reviews Clinical Oncology

Volumn 7, Issue 4, 2010, Pages 187-188

  Amir, Eitan ^a   Ocãa, Alberto ^a   Seruga, Bostjan ^a   Josse, Robert ^b   Clemons, Mark ^c  

^a UNIVERSITY OF TORONTO   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c OTTAWA REGIONAL CANCER CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; ZOLEDRONIC ACID;

BREAST CANCER; FRACTURE; HUMAN; OSTEOLYSIS; POSTMENOPAUSE; PRIORITY JOURNAL; SHORT SURVEY; SIDE EFFECT;

ABSORPTIOMETRY, PHOTON; AROMATASE INHIBITORS; BIOLOGICAL MARKERS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BREAST NEOPLASMS; CONFIDENCE INTERVALS; DIPHOSPHONATES; FEMALE; FRACTURES, BONE; HEALTH STATUS INDICATORS; HUMANS; IMIDAZOLES; INCIDENCE; ODDS RATIO; RISK FACTORS; RISK REDUCTION BEHAVIOR;

EID: 77950498196     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2010.19     Document Type: Short Survey

References (10)

1. Howell, A. et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365, 60-62 (2005). (Pubitemid 40082147)
2. Brufsky, A. M. et al. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z.-FAsT study 36-month follow-up results. Clin. Breast Cancer 9, 77-85 (2009).
3. eidtmann, H. et al. The effect of zoledronic acid on aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36 months follow-up of ZO-FAsT. Cancer Res. 69, 74s (American Association for Cancer Research, 2009).
4. Lombarto, A. et al. effect of zoledronic acid on aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: e-ZO-FAsT 36-month follow up. Proc. American Soc. Clinical Oncology 213 (American society of Clinical Oncology, 2009).
5. seeman, e. is a change in bone mineral density a sensitive and specific surrogate of antifracture efficacy? Bone 41, 308-317 (2007). (Pubitemid 47199158)
6. Forbes, J. F. et al. effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 9, 45-53 (2008).
7. Gnant, M. et al. endocrine therapy plus zoledronic acid in premenopausal breast cancer. N. Engl. J. Med. 360, 679-691 (2009).
8. Coleman, R. et al. impact of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAsT, ZO-FAsT, and e-ZO-FAsT. Cancer Res. 69, 733s (American Association for Cancer Research, 2009).
9. ellis, G. K. et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J. Clin. Oncol. 26, 4875-4882 (2008).
10. woodward, e. J. et al. Five year efficacy in cancer survivors of a single dose of zoledronic acid 4 mg in osteopenia and annual dosing in osteoporosis. The IX International Meeting on Cancer Induced Bone Disease (Cancer and Bone society, 2009).